Pathway CH S&E Registry (SER)
Pathway CH S&E Registry: Data Collection on the ATI Neurostimulation System: SPG Stimulation for Cluster Headache - ATI Neurostimulation System is Branded Internationally as Pulsante™ Microstimulator System
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Glostrup, Denmark, 2600
- Rigshospitalet Neurocenter
-
-
-
-
-
Dresden, Germany, 01307
- Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Klinik und Poliklinik für Neurologie
-
Düsseldorf, Germany, D-40225
- Heinrich-Heine-University
-
Freiburg, Germany, 79106
- Universitätsklinikum Freiburg
-
Kassel, Germany, 34121
- Klinik für Schmerztherapie, Rotes Kreuz Krankenhaus, Hansteinstr. 29
-
Munich, Germany, 80802
- Neurologie + Kopfschmerzzentrum Münchner Freiheit
-
-
-
-
-
Stockholm, Sweden, 17176
- Neurologiska Kliniken-Karolinska UniversitetssjukhusetSolna
-
-
-
-
-
Zurich, Switzerland, 8091
- University Hospital Zurich, Klinik f. Neurologie, Frauenklinikstr. 26
-
-
-
-
-
Liverpool, United Kingdom, L97LJ
- The Walton Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient meets CE marked labeling for cluster headache.
- Patient has the ability to read, comprehend and reliably record information as required by the Protocol.
- Patient is able to provide written informed consent prior to participation in the study.
Exclusion Criteria:
1. Patient has other significant pain problem that might confound the study assessments in the opinion of the Investigator.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Characterization of all device/procedure related Adverse Events
Time Frame: Through five years post implant
|
Outcome will be assessed at Implant, 3, 6, 9, 12, 18, 24, 36, 48 and 60 months post implant.
|
Through five years post implant
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Acute response to therapy
Time Frame: Through five years post implant
|
Outcome will be assessed at 3, 6, 9, 12, 18, 24, 36, 48 and 60 months post implant.
|
Through five years post implant
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CP-010
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cluster Headache
-
NCT00399243UnknownEpisodic Cluster Headache | Chronic Cluster Headache
-
NCT02797951CompletedEpisodic Cluster Headache | Chronic Cluster Headache
-
NCT05868044Active, not recruitingChronic Cluster Headache
-
NCT07113470Recruiting
-
NCT01341548Not yet recruitingEpisodic Cluster Headache
-
NCT02964338Terminated
-
NCT02438826CompletedChronic Cluster Headache
-
NCT03244735Completed
-
NCT02462395Completed